Bacil Pharma Stock Screener | Share Price & Fundamental Analysis
BACPHAR
Pharmaceuticals
Screen Bacil Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹42.74
▲
0.23 (0.54%)
Market Cap
₹51.88 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.86
EPS (TTM)
₹0.64
Dividend Yield
-
Debt to Equity
0.01
52W High
₹47.88
52W Low
₹28.09
Operating Margin
-
Profit Margin
100.00%
Revenue (TTM)
₹1.00
EBITDA
₹1.00
Net Income
₹1.00
Total Assets
₹26.00
Total Equity
₹25.00
Bacil Pharma Share Price History - Stock Screener Chart
Screen BACPHAR historical share price movements with interactive charts. Analyze price trends and patterns.
Bacil Pharma Company Profile - Fundamental Screener
Screen Bacil Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BACPHAR shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE711D01018
Bacil Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen BACPHAR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 26 | 1 | 1 | 1 | 4 | 4 | 5 | 5 | 7 | 7 |
| Current Assets | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Fixed Assets | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 3 | 6 | 5 |
| Liabilities | ||||||||||
| Total Liabilities | 26 | 1 | 1 | 1 | 4 | 4 | 5 | 5 | 7 | 7 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 25 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 6 | 6 |
| Share Capital | 14 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Reserves & Surplus | 12 | -5 | -5 | -5 | -5 | -5 | -5 | -4 | 0 | 0 |
Screen BACPHAR income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | 1 | 0 | 0 | 0 | -4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 0 | 0 | 0 | -4 | 0 | 0 | 0 | -4 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 0 | 0 | 0 | -4 | 0 | 0 | 0 | -4 | 0 | 0 | 0 |
| EPS | 0.40 | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 | -0.54 | -0.58 | -6.37 | 0.00 | -0.11 | -0.05 |
Bacil Pharma Cash Flow Screener - Liquidity Fundamentals
Screen BACPHAR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 0 | 0 | 0 | -4 | 0 | 0 | 0 | 1 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 4 | 1 | 0 | 0 | -1 | 0 | 0 |
| Financing Activities | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Screen BACPHAR shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Jul | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 0.20% | 0.20% | 0.08% | 0.08% | 42.67% | 42.67% | 20.70% | 10.60% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 75.77% | 77.37% | 79.74% | 80.95% | 53.89% | 53.91% | 59.61% | 67.42% |
| Other Holding | 24.03% | 22.43% | 20.18% | 18.97% | 3.44% | 3.42% | 19.69% | 21.98% |
| Shareholder Count | 7,638 | 7,532 | 7,541 | 7,431 | 6,770 | 6,794 | 6,902 | 7,461 |
Bacil Pharma Dividend Screener - Share Yield Analysis
Screen BACPHAR dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Bacil Pharma Index Membership - Market Screener Classification
Screen BACPHAR by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Bacil Pharma Market Events Screener - Corporate Actions
Screen BACPHAR market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 15.34% | ||
| Annual General Meeting | NA | 31.36% | ||
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -6.67% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -0.21% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 0.00% |
| 2025-01-21 | 2025-01-21 | Quarterly Result Announcement | NA | -8.02% |
| 2024-11-14 | 2024-11-14 | Extraordinary General Meeting | NA | 26.52% |
| 2024-10-23 | 2024-10-23 | Quarterly Result Announcement | NA | 10.34% |
Bacil Pharma Competitors Screener - Peer Comparison
Screen BACPHAR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 424,634 | 39.93 | 54,729 | 9.71% | 10,980 | 49.55 |
| Divis Laboratories | 172,860 | 69.20 | 9,712 | 18.67% | 2,191 | 56.33 |
| Torrent Pharmaceuticals | 129,151 | 60.10 | 11,539 | 6.99% | 1,911 | 61.47 |
| Cipla | 122,205 | 22.55 | 28,410 | 7.12% | 5,291 | 49.47 |
| Dr Reddys Laboratories | 107,114 | 18.60 | 33,741 | 16.73% | 5,725 | 60.05 |
| Lupin | 97,120 | 22.34 | 22,910 | 13.74% | 3,306 | 65.28 |
| Zydus Life Science | 92,392 | 18.40 | 23,511 | 18.55% | 4,615 | 40.07 |
| Mankind Pharma | 90,241 | 50.59 | 12,744 | 20.90% | 2,007 | 45.53 |
| Aurobindo Pharma | 71,119 | 20.79 | 32,346 | 9.43% | 3,484 | 59.88 |
| Alkem Laboratories | 67,243 | 27.59 | 13,458 | 3.70% | 2,216 | 49.80 |
Bacil Pharma Company Announcements - News Screener
Screen BACPHAR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-06 | Appointment of Company Secretary and Compliance Officer | View |
| 2025-12-01 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | View |
| 2025-11-13 | Un-Audited Financial Result For 30Th September 2025 | View |
| 2025-11-13 | Board Meeting Outcome for Outcome Of Board Meeting Held On 13Th November 2025 | View |
| 2025-11-05 | Board Meeting Intimation for We Wish To Inform That The Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Thursday 13Th November 2025 | View |
| 2025-10-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-29 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-27 | Closure of Trading Window | View |
| 2025-09-05 | Book Closure For The Purpose Of Annual General Meeting | View |
| 2025-09-05 | Reg. 34 (1) Annual Report. | View |
| 2025-09-05 | Notice Of 38Th Annual General Meeting Of The Company | View |
| 2025-09-05 | Board Meeting Outcome for Outcome Of Board Meeting Held On 05Th September 2025 | View |
| 2025-09-04 | INTIMATION OF RECEIPT OF REQUEST FOR RECLASSIFICATION OF THE PROMOTER IN ACCORDANCE WITH REGULATION 31A OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS 2015. | View |
| 2025-09-02 | Board Meeting Intimation for We Hereby Notify You That A Meeting Of The Board Of Directors Of Bacil Pharma Limited ("The Company") Will Be Held On 05Th September 2025. | View |
| 2025-08-27 | Board Meeting Outcome for Revised Outcome Of Board Meeting Held On 25Th August 2025 | View |
| 2025-08-27 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | View |
| 2025-08-27 | Board Meeting Outcome for Revised Outcome Of Board Meeting Held On 25Th August 2025 | View |
| 2025-08-25 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | View |
| 2025-08-25 | Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th August 2025 | View |